Valuation: AstraZeneca PLC

Market Cap 29TCr 4,46,13400Cr 26TCr 24TCr 22TCr 40TCr 27,54300Cr 41TCr 2,85000Cr 1,14400Cr 14,48800Cr 1,08900Cr 1,06500Cr 45,69100Cr P/E 2026 *
24.5x
P/E 2027 * 20.9x
Enterprise Value 31TCr 4,75,73900Cr 28TCr 25TCr 23TCr 43TCr 29,37000Cr 44TCr 3,03900Cr 1,22000Cr 15,45000Cr 1,16100Cr 1,13600Cr 48,72300Cr EV / Sales 2026 *
4.89x
EV / Sales 2027 * 4.5x
Free-Float
96.62%
Yield 2026 *
1.77%
Yield 2027 * 1.9%
1 day+7.48%
1 week+9.15%
Current month+18.08%
1 month+18.08%
3 months+15.22%
6 months+9.50%
Current year+9.46%
1 week 70,075
Extreme 70075
77,950
1 month 62,475
Extreme 62475
77,950
Current year 60,650
Extreme 60650
80,275
1 year 60,650
Extreme 60650
80,275
3 years 24,288
Extreme 24288
80,275
5 years 5,438.5
Extreme 5438.5
80,275
10 years 214.5
Extreme 214.5
80,275
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+7.48%+9.15% - - 29TCr
+3.19%+11.31%+67.86%+150.58% 1,26300Cr
-0.73%+3.56%+44.51%+85.81% 66TCr
+1.41%+3.24%+29.22%+107.83% 52TCr
+0.42%+3.20%+54.15%+67.18% 39TCr
+2.18%+2.93%+73.30%+45.62% 37TCr
+1.12%+4.52%+35.30%+58.08% 31TCr
+6.96%+8.86%+11.27%+36.62% 29TCr
+1.15%+6.09%+59.59%+77.06% 25TCr
+3.06%+9.38%+44.11%+119.47% 21TCr
Average +2.30%+5.90%+46.59%+83.14% 47.35TCr
Weighted average by Cap. +1.59%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 6.33TCr 97,35600Cr 5.67TCr 5.21TCr 4.72TCr 8.83TCr 6,01000Cr 9TCr 62TCr 25TCr 3,16200Cr 24TCr 23TCr 9,97100Cr 6.74TCr 1,03,63800Cr 6.03TCr 5.55TCr 5.03TCr 9.4TCr 6,39800Cr 9.58TCr 66TCr 27TCr 3,36600Cr 25TCr 25TCr 10,61400Cr
Net income 1.17TCr 18,06900Cr 1.05TCr 967.83Cr 876.93Cr 1.64TCr 1,11600Cr 1.67TCr 12TCr 4.63TCr 59TCr 4.41TCr 4.32TCr 1,85100Cr 1.37TCr 21,04800Cr 1.23TCr 1.13TCr 1.02TCr 1.91TCr 1,29900Cr 1.95TCr 13TCr 5.4TCr 68TCr 5.14TCr 5.03TCr 2,15600Cr
Net Debt 1.92TCr 29,60500Cr 1.72TCr 1.59TCr 1.44TCr 2.69TCr 1,82800Cr 2.74TCr 19TCr 7.59TCr 96TCr 7.22TCr 7.07TCr 3,03200Cr 1.33TCr 20,42200Cr 1.19TCr 1.09TCr 991.15Cr 1.85TCr 1,26100Cr 1.89TCr 13TCr 5.24TCr 66TCr 4.98TCr 4.88TCr 2,09200Cr
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
30/26/30 ARS 77,225.00 +7.48% 3,130
29/26/29 ARS 71,850.00 +2.46% 670
28/26/28 ARS 70,125.00 -0.14% 1,098
27/26/27 ARS 70,225.00 -2.40% 1,297
26/26/26 ARS 71,950.00 +1.70% 913
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
187.02USD
Average target price
210.53USD
Spread / Average Target
+12.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC